Company logo
Global Narcolepsy Drug Market
Global Narcolepsy Drug Market
Dublin, July 30, 2024 (GLOBE NEWSWIRE) — The “Global Narcolepsy Drugs Market Report by Therapeutic Type, Disease Type, End User, Countries and Company Analysis, 2024-2032” report has been added to ResearchAndMarkets.com’s offering.
The global narcolepsy medication market is expected to grow from USD 3.47 billion in 2023 to over USD 6.94 billion by 2032, at a compound annual growth rate (CAGR) of 8.01% from 2024 to 2032. The growth of the industry is driven by increasing awareness of narcolepsy, new medications, and rising healthcare costs.
Narcolepsy Drugs Market Growth Factors:
Improved understanding and diagnosis
Technological advances in drug development
Increasing medical costs
Narcolepsy Drug Market in Asia
Narcolepsy Drug Global Company News
March 2024: Avadel Pharmaceuticals Inc. reports in its fourth quarter and full year 2023 update that more than 1,200 patients have started using Lumryz, a new narcolepsy medication taken once before bed. Additionally, more than 2,200 patients have enrolled in the RYZUP patient assistance program, many of whom are switching from first-generation oxybates. The program is open to patients who have never used oxybates before, as well as those who were previously using first-generation oxybates and discontinued.
January 2024: Jazz Pharmaceuticals, Inc. and UCB (Euronext Brussels: UCB) have entered into an enhanced product license agreement for Xyrem (oxybutosodium). Under the terms of the agreement, UCB will have the exclusive right to market Xyrem as a treatment for fibromyalgia syndrome if approved for this indication. On September 7, 2006, Jazz Pharmaceuticals initiated a Phase 3 clinical development program for Xyrem as a treatment for fibromyalgia syndrome.
October 2023: EnsoData and React Health partner to support patients with sleep apnea by integrating predictive AI into React Health’s platform, making information more accessible to physicians and equipment providers and helping patients adhere to their treatment plans.
Disease type – Analyzing the market from three perspectives
Treatment Type – Five Perspectives to Analyze the Market
Stimulants
Tricyclic antidepressants
Sodium oxybate
Selective serotonin reuptake inhibitors
others
End users – Analyzing the market from three perspectives
Diagnostic Center
hospital
others
Geography – Market breakdown across 17 countries
North America
America
Canada
Mexico
Brazil
Europe
England
Germany
France
Italy
Spain
Netherlands
Asia Pacific
China
Japan
India
South Korea
Australia
Middle East and Africa
South Africa
United Arab Emirates
The story continues
Key Player Analysis
Company Information
overview
Recent developments
Product Portfolio
Financial Insights
Major features
Report Attributes
detail
number of pages
170
Forecast Period
2023-2032
Estimated market value in 2023 (USD)
$3.47 billion
Market value forecast to 2032 (USD)
$6.95 billion
Compound Annual Growth Rate
8%
Target area
global
For more information on this report, please visit: https://www.researchandmarkets.com/r/ikkxfa
About ResearchAndMarkets.com
ResearchAndMarkets.com is a leading global source of international market research reports and market data providing the latest information on international markets, regional markets, key industries, top companies, new products and latest trends.
Attachments
Contact Information: Contact Us: ResearchAndMarkets.com Laura Wood, Sr. Press Manager press@researchandmarkets.com For EST office hours, please call 1-917-300-0470 For US/Canada toll free, please call 1-800-526-8630 For GMT office hours, please call +353-1-416-8900
Source link
